BrainStorm Cell Therapeutics Reports Promising Q1 2025 Financial Results and Updates on Pipeline Developments BrainStorm Cell Therapeutics has shared its Q1 2025 financial results along with significant updates regarding its NurOwn therapy for ALS, showcasing promising developments.

BrainStorm Cell Therapeutics Reports Promising Q1 2025 Financial Results and Updates on Pipeline Developments #United_States #New_York #ALS_Treatment #NurOwn #BrainStorm_Cell